Lista de obras -

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

artículo científico publicado en 2017

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial

artículo científico publicado en 2017

Cancer Testis Antigen Expression Across T-Cell Lymphoma Subtypes

artículo científico publicado en 2020

Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study

artículo científico publicado en 2020

Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas

artículo científico publicado en 2012

Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas

artículo científico publicado en 2005

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

artículo científico publicado en 2008

Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma

artículo científico publicado en 2004

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

artículo científico publicado en 2005

Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

artículo científico publicado en 2020

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL ⬇️

artículo científico publicado el 19 de julio de 2011

High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience

artículo científico publicado en 2004

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma

artículo científico publicado en 2007

Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays

artículo científico publicado en 2005

Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.

artículo científico publicado en 2004

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

artículo científico publicado en 2020

New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination

scientific article published on 27 February 2019

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

artículo científico publicado en 2017

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

artículo científico publicado en 2019

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

artículo científico publicado en 2007

Pralatrexate Pharmacology and Clinical Development ⬇️

artículo científico publicado el 21 de agosto de 2013

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

artículo científico publicado en 2010

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma

artículo científico publicado en 2007

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center pha

artículo científico publicado en 2020

Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action

artículo científico publicado en 2013

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

artículo científico publicado en 2009

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma

artículo científico publicado en 2010

Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ⬇️

artículo científico publicado el 1 de agosto de 2012

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma ⬇️

artículo científico publicado el 2 de agosto de 2013

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

artículo científico publicado en 2018

Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials

artículo científico publicado en 2019

The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.

artículo científico publicado en 2009

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

scientific article published on 05 May 2020

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

artículo científico publicado en 2015

The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma

artículo científico publicado en 2015

The peripheral T-cell lymphomas: an unusual path to cure

scientific article published on 01 October 2020

The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management

scientific article published on 09 December 2019

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

artículo científico publicado en 2007

Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma

artículo científico publicado en 2005

Lista de obras de

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial

Cancer Testis Antigen Expression Across T-Cell Lymphoma Subtypes

Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study

Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas

Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL ⬇️

High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma

Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays

Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

Pralatrexate Pharmacology and Clinical Development ⬇️

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center pha

Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma

Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ⬇️

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma ⬇️

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials

The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma

The peripheral T-cell lymphomas: an unusual path to cure

The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma